Calcipotriol/betamethasone dipropionate foam demonstrates comparable efficacy to clinical trial data in the real world, improves patient satisfaction and is cost‐effective

Real-world evidence studies are becoming increasingly important in providing insight into clinical effectiveness and safety, economic outcomes, patient-reported outcomes health-related quality of life treatments the setting. These also help to complement data reported studies. Fixed-dose combination calcipotriol 50 µg/g plus betamethasone dipropionate 0.5 mg/g cutaneous foam (Cal/BD foam) is a topical agent used for treatment psoriasis vulgaris. In studies, Cal/BD has demonstrated significantly greater efficacy rapid onset action compared with both single formulations such as ointments gels. To date, three observational have examined real-world safety practice United States, Germany Spain. Data gathered from these reinforce positive findings assessing demonstrate improved patient satisfaction foam. Using been shown be cost-effective based on results randomised trials analysis. As such, potential lower costs by reducing need some patients progress more expensive treatments, phototherapy biologics. therefore solution vulgaris that should considered when prescribing topicals.